


In the Claims:

1. (Currently Amended) A compound of formula (I)



wherein

R¹ is lower alkyl, or lower alkyl substituted by cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R², R³ and R⁴ are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl are optionally substituted by lower alkoxy-carbonyl, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl;

R⁵ is hydrogen, fluorine, lower alkyl, aryl or substituted aryl;

R⁶ is hydrogen, lower alkyl or hydroxy-lower alkyl, or

R⁵ and R⁶ together with the carbon atoms to which they are attached form a five or six membered saturated carbocyclic ring;

R⁷ is hydrogen, fluorine or lower alkyl;

wherein substituted aryl is aryl that is mono-, di- or tri-substituted by lower alkyl, lower alkoxy, halo, cyano, azido, amino, di-lower alkyl amino or hydroxy;

substituted heteroaryl is heteroaryl that is mono-, di- or tri-substituted by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy;

substituted heterocyclyl is heterocyclyl that is mono-, di- or tri-substituted by lower alkyl, lower alkoxy, halo, cyano, azido, amino, di-lower alkyl amino or hydroxyl;

and pharmaceutically acceptable salts thereof;

BEST AVAILABLE COPY

with the exception of *rac*-3 β -Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine dihydrochloride, ~~and *rac*-3 β -Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine dihydrochloride,~~
3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,
rac-3 β -methyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine dihydrochloride,
rac-3 β -methyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine dihydrochloride, and
3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine.

2. (Currently Amended) The compound according to claim 1, wherein R¹ is lower alkyl, ~~aryl, substituted aryl, or lower alkyl substituted by cycloalkyl, aryl or substituted aryl;~~
R², R³ and R⁴ are each independently hydrogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl are optionally substituted by lower alkoxy, carbonyl, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl;
R⁵ and R⁶ are each independently hydrogen, lower alkyl, aryl, substituted aryl, or, together with the carbon atoms to which they are attached form a five or six membered saturated carbocyclic ring.

3. (Canceled)

4. (Previously Presented) The compound according to claim 1, wherein R¹ is lower alkyl or lower alkyl substituted by cycloalkyl.

5. (Canceled)

6. (Original) The compound according to claim 1, wherein R², R³ and R⁴ are each independently hydrogen, hydroxy, lower alkoxy; or lower alkoxy substituted by aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, or lower alkoxy, carbonyl.

BEST AVAILABLE COPY

7. (Original) The compound according to claim 6, wherein R^2 , R^3 and R^4 are each independently lower alkoxy substituted by phenyl or phenyl substituted by di-lower alkyl amino or cyano.

8. (Previously Presented) The compound according to claim 6, wherein R^2 is lower alkoxy.

9. (Previously Presented) The compound according to claim 6, wherein R^3 is lower alkoxy, hydrogen, hydroxy; or lower alkoxy substituted by aryl, substituted aryl, heterocyclyl, substituted heterocyclyl or lower alkoxycarbonyl.

10. (Original) The compound according to claim 9, wherein R^3 is lower alkoxy, hydrogen or hydroxy.

11. (Previously Presented) The compound according to claim 6, wherein R^4 is lower alkoxy, hydrogen or hydroxy.

12. (Original) The compound according to claim 1, wherein R^5 and R^6 are hydrogen or, together with the carbon atoms to which they are attached, form a six membered saturated carbocyclic ring.

13. (Previously Presented) The compound according to claim 1, selected from the group consisting of:

rac-9,10-dimethoxy-3 β -propyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-9,10-dimethoxy-3 β -(3-methyl-butyl)-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -cyclopropylmethyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-7 β -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine,

rac-3 β -butyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine chlorohydrate (1:2),
rac-9,10-dimethoxy-3 β -propyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine chlorohydrate (1:2),
rac-7 β -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine chlorohydrate (1:2),
rac-2 β -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol chlorohydrate (1:2),
rac-2 α -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol chlorohydrate (1:2),
rac-2 β -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol, and
rac-2 α -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol;
or a pharmaceutically acceptable salt thereof.

14. (Currently Amended) The compound according to claim 1, selected from the group consisting of:

rac-9,10-dimethoxy-3 β -(3-methyl-butyl)-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,
rac-7 β -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine,
rac-3 β -butyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine chlorohydrate (1:2),
rac-7 β -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine chlorohydrate (1:2),
rac-2 α -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol chlorohydrate (1:2), and
rac-2 α -amino-3 β -butyl-10-methoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-

ol, and

~~rac-9,10-dimethoxy-3 β -phenyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine.~~

15. (Previously Presented) The compound according to claim 1, selected from the group consisting of:

rac-4-(2 β -Amino-3 β -butyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-7 β -yl)-phenol,

rac-3 β -Butyl-9,10-dimethoxy-6-methyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,

rac-3 β -Butyl-7 β -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-7 α -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-7 β -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-7 β -Butyl-11,12-dimethoxy-2,3,4,4a β ,6,7,8,9,9a α ,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine,

rac-7 β -Butyl-11,12-dimethoxy-2,3,4,4a β ,6,7,8,9,9a α ,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 α -ylamine,

rac-3 β -Butyl-7 α -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-6 α -methyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,

rac-7 β -Butyl-11,12-dimethoxy-13b-methyl-2,3,4,4a β ,6,7,8,9,9a,13b-decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine,

REST AVAILABLE COPY

(6S)-(2-Amino-3-butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-6-yl)-methanol,

rac-4-(2 β -Amino-3 β -butyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-7-yl)-phenol,

rac-4-(2 β -Amino-3 β -butyl-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-7 β -yl)-phenol,

rac-3 β -Butyl-9,10-dimethoxy-6-methyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,

rac-3 β -Butyl-7 β -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-7 α -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-7 β -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 α -Butyl-7 β -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-3 β -Butyl-7 β -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-3 β -Butyl-7 α -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7 β -(4-methoxy-phenyl)-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7 β -(4-methoxy-phenyl)-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 α -ylamine,

rac-3 β -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 β -ylamine,

rac-7 β -Butyl-11,12-dimethoxy-2,3,4,4a β ,6,7,8,9,9a α ,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 β -ylamine,
rac-7 β -Butyl-11,12-dimethoxy-2,3,4,4a β ,6,7,8,9,9a α ,13b β -decahydro-1H-pyrido[1,2-f]phenanthridin-8 α -ylamine, and
rac-3 β -Butyl-7 α -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-6 α -methyl-1,3,4,6,7,11b β -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine;
or a pharmaceutically acceptable salt thereof.

16. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

17. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of diabetes or non-insulin dependent diabetes mellitus, which comprises administering to a patient in need of ~~treatment thereof~~ a therapeutically effective amount of a compound according to claim 1 in an amount of from about 1 to 1000 mg per day.

18. (Original) The method according to claim 17, wherein the amount administered is a daily dosage of from about 1 to 100 mg.

BEST AVAILABLE COPY